AUTHORS
Huafeng Wang, MD, Miaomiao Liu2, Jie Jin, MD3, Yinghui Zhu, PhD4
AFFILIATIONS
1 the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 School of Life Sciences and Technology, Tongji University, SHANGHAI, China
3 the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
4 School of Life Sciences and Technology, Tongji University, SHANGHAI, China
ABSTRACT
Introduction
Resistance to venetoclax (Ven)-based regimens is a major clinical bottleneck in AML. While alternative anti-apoptotic signaling and canonical lipid pathways are implicated, how resistant cells exploit non-canonical carbon sources remain obscure. Although our recent phase II clinical trial demonstrated high remission rates using the Ven-DAV combination (daunorubicin-D, cytarabine-A, venetoclax-V,) in adult AML patients, intrinsic resistance persists in a subset. This study aims to decipher the determinants driving this resistance and identify novel therapeutic vulnerabilities.
Methods
We performed integrated, unbiased TMT-labeled quantitative proteomic profiling on bone marrow samples from a cohort of 33 newly diagnosed AML patients stratified by clinical response (complete remission: CR vs. non- responder: NR) to DA or Ven-DAV regimens. Transcriptomic panels and validation cohorts were evaluated for prognostic clinical relevance. Targeted LC-MS/MS was developed to quantify intracellular ketone kinetics. Functional validation was conducted in AML cell lines, primary blasts, and MLL-AF9-driven conditional knockout mouse models via BMT, ATAC-seq, ChIP-seq, and mouse models.
Results
High-resolution proteomic profiling identified 7,672 reliably quantified proteins, revealing that DAV-NR AML patients exhibit a significantly more complex proteomic landscape (203 DEPs) compared to DA resistance (71 DEPs). Tissue-specific and functional enrichment analysis tied these alterations directly to CD34? progenitors and metabolic rewiring. Protein-protein interaction networks identified a tightly connected cluster of mitochondrial enzymes, pinpointing 3-oxoacid CoA-transferase 1 (OXCT1), the rate-limiting enzyme of ketolysis, as the central network hub significantly enriched in NR patients. Across three independent cohorts (TCGA, GSE10358, ca00119), elevated OXCT1 robustly correlated with poor overall survival. Targeted metabolomics confirmed accelerated ketolytic flux in DAV-NR bone marrow samples, characterized by a marked depletion of the primary substrate β-HB (DAV-NR: n=4; DAV-CR: n=6; p=0.0088) and significant accumulation of the direct product acetoacetyl-CoA (p=0.038).
Genetic ablation of OXCT1 induced apoptosis and restored Ven sensitivity in AML cells including THP1/OCI-AML3/HEL, whereas its overexpression conferred resistance. To evaluate its physiological role, we retrovirally transduced Oxct1-/- and Oxct1+/+ Lin- bone marrow cells with the MLL-AF9 oncogene. Oxct1 deletion markedly impaired leukemic transformation in vitro, significantly reducing colony-forming capacity. In serial bone marrow transplantation assays, secondary recipients of Oxct1-/- leukemic cells exhibited delayed disease progression, decreased CD45.2+ blast frequencies across the bone marrow, spleen, liver, and peripheral blood, and attenuated splenomegaly and tissue infiltration. Crucially, in tertiary transplantation assays, recipients of Oxct1 cells showed significantly prolonged survival, confirming impaired leukemia-initiating cell self-renewal (median survival: 116 vs. 39 days in Ctrl; p=0.0065), while OXCT1 remained dispensable for normal hematopoiesis.
Mechanistically, metabolomic flux mapping revealed that OXCT1-derived acetyl-CoA fuels mitochondrial bioenergetics via the TCA cycle. Intriguingly, it concurrently acts as a pivotal metabolic-epigenetic bridge; OXCT1-derived acetyl-CoA directly promotes histone acetylation, which sustains chromatin accessibility and transcriptionally activates the key MYB-driven oncogenic program. Furthermore, pharmacological inhibition of OXCT1 using pimozide synergistically enhanced the efficacy of Ven-based combinations. In vitro, the combination of pimozide and venetoclax exerted potent synergistic cytotoxicity in the THP-1 cells as well as in primary blasts isolated from five AML patients (n=5). Consistently, in a THP1-derived CDX model, combining pimozide with Ven significantly reduced leukemic burden and prolonged median survival (p=0.02).
Conclusions
Our study elucidates a novel metabolic-epigenetic circuitry mediated by the OXCT1-ketolysis-MYB axis in driving AML maintenance and drug resistance. These findings reposition ketolysis from a peripheral energy pathway to a central epigenetic regulator, positioning OXCT1 as a highly promising and selective therapeutic target to overcome resistance to venetoclax-based regimens.
DISCLOSURES
Yinghui Zhu, PhD: No relevant conflicts of interest to declare.